Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kura Oncology, Inc.KURA · Entity 4871 | Chief Operating Officer | May 19, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kura Oncology, Inc.
Report date May 19, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,560 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Sale · Disposed 2,257 · Balance 153,560 F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2025. F2: 2,257 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. F3: This transaction was executed in multiple trades at prices ranging from $8.97 to $9.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2025.
F2: 2,257 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
F3: This transaction was executed in multiple trades at prices ranging from $8.97 to $9.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 20, 2026 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,257 | $9.08 | $20,482.73 |
DisclosureSEC source: 0001193125-26-232548 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,560 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2025. F2 · shares: 2,257 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $8.97 to $9.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,813 | $8.46 | $15,339.25 |
DisclosureSEC source: 0001193125-26-025304 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,560 F1 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 100,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004567 · ownership.xml · derivative · entry 2 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004567 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,373 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,902 | $11.18 | $77,142.96 |
DisclosureSEC source: 0001193125-25-283560 · ownership.xml · nonDerivative · entry 2 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,373 F1 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 48,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-283560 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,275 Read SEC document |
| September 29, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,892 | $8.94 | $61,629.64 |
DisclosureSEC source: 0001193125-25-223665 · ownership.xml · nonDerivative · entry 2 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,375 F1 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on September 27, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| September 27, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 48,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-223665 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,267 Read SEC document |
| May 19, 2025 Filed May 19, 2025 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,558 | $6.28 | $9,777.38 |
DisclosureSEC source: 0000950170-25-074659 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,367 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2024. F2 · shares: 1,558 shares were acquired on May 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $6.27 to $6.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,817 | $7.87 | $14,303.24 |
DisclosureSEC source: 0000950170-25-010118 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,367 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 185,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0000950170-25-002049 · ownership.xml · derivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 526 | $16.03 | $8,433.73 |
DisclosureSEC source: 0000950170-24-128558 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,184 F1 · shares: 526 shares were acquired on November 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.78 to $16.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 1,582 shares acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,496 | $17.80 | $26,629.55 |
DisclosureSEC source: 0000950170-24-009494 · ownership.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,602 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. F2 · balance_after: Includes 1,884 shares acquired on November 17, 2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 185,000 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0000950170-24-001846 · ownership.xml · derivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:11 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 185,000 | $0.00 Strike: $11.99 | $0.00 |
DisclosureSEC source: 0001209191-23-011285 · doc4.xml · derivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:20 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,821 | $13.89 | $25,293.87 |
DisclosureSEC source: 0001209191-23-005753 · doc4.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,214 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:15 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 171,000 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0001209191-22-005380 · doc4.xml · derivative · entry 2 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,000 Underlying: Common Stock · 171,000 shares Expires 2032-01-25 F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:15 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 21,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005380 · doc4.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,035 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26. F2 · balance_after: Includes 1,135 shares acquired on May 20, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:17 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 6,250 | $0.00 Strike: $19.43 | $0.00 |
DisclosureSEC source: 0001209191-21-021320 · doc4.xml · derivative · entry 3 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,625 Underlying: Common Stock · 6,250 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on August 9, 2019. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:17 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,250 | $29.43 | $183,950.63 |
DisclosureSEC source: 0001209191-21-021320 · doc4.xml · nonDerivative · entry 2 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $29.43 to $29.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:17 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 6,250 | $19.43 | $121,437.50 |
DisclosureSEC source: 0001209191-21-021320 · doc4.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 22:28 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 140,000 | $0.00 Strike: $32.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005910 · doc4.xml · derivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 9,375 | $0.00 Strike: $19.43 | $0.00 |
DisclosureSEC source: 0001209191-20-063764 · doc4.xml · derivative · entry 5 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,875 Underlying: Common Stock · 9,375 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. F4 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on August 9, 2019. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 3,125 | $40.60 | $126,885.94 |
DisclosureSEC source: 0001209191-20-063764 · doc4.xml · nonDerivative · entry 4 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $40.06 to $41.315. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 3,125 | $19.43 | $60,718.75 |
DisclosureSEC source: 0001209191-20-063764 · doc4.xml · nonDerivative · entry 3 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,250 | $40.60 | $253,780.63 |
DisclosureSEC source: 0001209191-20-063764 · doc4.xml · nonDerivative · entry 2 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.07 to $41.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 6,250 | $19.43 | $121,437.50 |
DisclosureSEC source: 0001209191-20-063764 · doc4.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 6,250 | $0.00 Strike: $19.43 | $0.00 |
DisclosureSEC source: 0001209191-20-058020 · doc4.xml · derivative · entry 3 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,250 Underlying: Common Stock · 6,250 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on August 9, 2019. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,250 | $39.43 | $246,437.50 |
DisclosureSEC source: 0001209191-20-058020 · doc4.xml · nonDerivative · entry 2 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 6,250 | $19.43 | $121,437.50 |
DisclosureSEC source: 0001209191-20-058020 · doc4.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| September 15, 2020 Filed Sep 15, 2020 23:25 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 6,250 | $0.00 Strike: $19.43 | $0.00 |
DisclosureSEC source: 0001209191-20-050596 · doc4.xml · derivative · entry 6 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,500 Underlying: Common Stock · 6,250 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on August 9, 2019. Read SEC document |
| September 15, 2020 Filed Sep 15, 2020 23:25 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,250 | $29.43 | $183,937.50 |
DisclosureSEC source: 0001209191-20-050596 · doc4.xml · nonDerivative · entry 4 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| September 15, 2020 Filed Sep 15, 2020 23:25 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 6,250 | $19.43 | $121,437.50 |
DisclosureSEC source: 0001209191-20-050596 · doc4.xml · nonDerivative · entry 3 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:25 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 6,250 | $0.00 Strike: $19.43 | $0.00 |
DisclosureSEC source: 0001209191-20-050596 · doc4.xml · derivative · entry 5 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 6,250 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on August 9, 2019. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:25 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,250 | $29.43 | $183,937.50 |
DisclosureSEC source: 0001209191-20-050596 · doc4.xml · nonDerivative · entry 2 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:25 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 6,250 | $19.43 | $121,437.50 |
DisclosureSEC source: 0001209191-20-050596 · doc4.xml · nonDerivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2020. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 45,393 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001209191-20-005979 · doc4.xml · derivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,393 Underlying: Common Stock · 45,393 shares Expires 2030-01-29 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 22:17 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 250,000 | $0.00 Strike: $19.43 | $0.00 |
DisclosureSEC source: 0001209191-19-045803 · doc4.xml · derivative · entry 1 FORD KATHLEEN · CIK 0001785406 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-08-08 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date of August 9, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.